Veterinary Medicines Directorate
class="gem-c-govspeak govuk-govspeak gem-c-govspeak--direction-ltr govuk-!-margin-bottom-0">
Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPCs) for the following have been updated:
- Librela 5mg Solution for Injection for Dogs
- Librela 10mg Solution for Injection for Dogs
- Librela 15mg Solution for Injection for Dogs
- Librela 20mg Solution for Injection for Dogs
- Librela 30mg Solution for Injection for Dogs
Section 4.6 now additionally states that in rare cases diarrhoea, emesis, ataxia, urinary incontinence, anorexia and lethargy have been reported. In very rare cases, seizure has been reported after administration of the veterinary medicinal product.
Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.
No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).
All updates to SPCs other than template changes, are published in the medicine updates section of